Clinical trial ME-401-003 (TIDAL)
A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | MEI Pharma |
| EudraCT Identifier | 2018-002896-17 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03768505 |
| Inclusion criteria | - relapsed or refractory follicular NHL grade 1-2-3a- has received at least 1 prior line of therapy- at least 1 lymph node of at least 1.5cm or 1 ectra nodal lesion > 1cm- QTcF < 450 msec |
| Last update |